Table 1.

Hypermethylation status of E-cadherin, p16, and RAR-β₂ for pre- and postmenopausal women, WEB Study, 1996–2001^a

Clinicopathologic factors	Premenopausal wemen						Postmenopausal women
	E-cadherin		p16		RAR-β2		E-cadherin		p16		RAR-β2
	Yes	No	Yes	No	Yes	No	Yes	No	Yes	No	Yes	No
Age at diagnosis (yr)
< 50	45	164	49	160	58	151	8	30	4	34	14	24
50–59	5	23	12	16	6	22	31	150	48	133	50	131
60–69	–	–	–	–	–	–	38	169	60	147	56	151
≥70	–	–	–	–	–	–	34	106	35	105	37	103
P-value		0.65		0.03		0.48		0.41		0.12		0.63
Education (yr)
< 12	3	5	2	6	2	6	10	36	13	33	13	33
12	18	49	13	54	21	46	46	187	61	172	68	165
≥12	29	133	46	116	41	121	55	232	73	214	76	211
P-value		0.16		0.37		0.64		0.92		0.92		0.79
Tumor size (cm)b
< 1.0 (0.9)	5	28	11	22	9	24	29	84	25	88	39	74
1.0–1.7 (0.9–1.4)	15	56	14	57	18	53	22	120	40	102	38	104
1.8–2.6 (1.5–1.9)	19	36	11	44	16	39	22	69	27	64	22	69
≥2.7 (2.0)	7	48	15	40	14	41	28	138	42	124	46	120
P-value		0.03		0.38		0.96		0.11		0.59		0.37
Metastatic disease at presentation
No	28	120	37	111	39	109	87	318	109	296	107	298
Yes	19	62	21	60	23	58	19	107	27	99	39	87
P-value		0.42		0.88		0.74		0.11		0.22		0.32
Vascular/lymph invasion
No	30	117	35	112	39	108	78	309	105	282	102	285
Yes	18	64	22	60	23	58	21	110	31	100	39	92
P-value		0.78		0.61		0.66		0.30		0.43		0.45
Histological grade
Well	3	16	0	19	8	11	13	50	19	44	20	43
Moderate	15	51	19	47	20	46	36	138	46	128	40	134
Poor	26	84	26	84	24	86	44	159	55	148	53	150
P-value		0.75		0.03		0.13		0.97		0.85		0.39
Nuclear grade
I	5	25	9	21	9	21	24	91	29	86	33	82
II	19	56	18	57	22	53	41	149	49	141	47	143
III	25	89	27	87	27	87	40	155	52	143	50	145
P-value		0.62		0.76		0.62		0.97		0.96		0.74
TNM stage
0	7	22	7	22	11	18	10	52	14	48	17	45
I	15	65	21	59	20	60	53	202	72	183	67	188
IIa/IIb	21	67	17	71	20	68	26	128	40	114	48	106
III/IV	2	21	9	14	10	13	4	20	2	22	8	16
P-value		0.40		0.25		0.12		0.71		0.18		0.69
ER status
+	28	112	36	104	43	97	81	310	92	299	111	280
−	16	64	22	58	16	64	29	124	48	105	39	114
P-value		1.0		0.77		0.08		0.64		0.06		0.50
PR status
+	28	120	40	108	39	109	59	266	78	247	94	231
−	16	51	15	52	19	48	46	156	56	146	53	149
P-value		0.40		0.47		0.76		0.20		0.34		0.50
ER/PR
Both +	23	98	29	92	36	85	56	240	70	226	86	210
Either +	10	32	17	25	8	34	22	85	27	80	29	78
Both −	11	39	9	41	13	37	26	94	37	83	30	90
P-value		0.77		0.04		0.40		0.80		0.31		0.70
p53 mutation
Wild	30	119	38	111	40	109	66	276	96	246	92	250
Mutant	15	49	16	48	17	47	25	104	34	95	38	91
P-value		0.59		0.94		0.97		0.98		0.71		0.58

^aSubjects with missing values were excluded from the analysis

^bCut-off point of tumor size among postmenopausal women